ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
14 announcements with these filters
NSE rejected Gufic Biosciences' waiver application regarding a ₹1.72 lakh penalty for Regulation 17(1A) non-compliance. The company will pay the fine by October 03, 2026.
Gufic Biosciences announced that CRISIL Ratings has reaffirmed its credit ratings on the company's total bank loan facilities of ₹516 Crore.
Gufic Biosciences held its 42nd Annual General Meeting on September 4, 2026, where shareholders adopted financial statements and approved the final dividend declaration.
Gufic Biosciences Limited announced the promotions of Ms. Ami Shah to Head-Legal and Mr. Pinak Padhya to President of Sales & Marketing, effective September 2, 2026.
Gufic reports strong Q1 FY27 growth, driven by Indore plant ramp-up and expansion into high-margin complex injectables like GLP-1 (Semaglutide) and Botulinum Toxin.
Gufic reported Q1 FY27 revenue of ₹260.8 Cr (+15% YoY) with EBITDA margins expanding to 18.09%. Strategy pivots toward IP-owned complex injectables and scaling the new Indore facility.
Gufic Biosciences will incorporate a new subsidiary, Gufic Philippines Inc, for ₹0.24 Crore. The entity will support the company's pharmaceutical business expansion in the Philippines.
Gufic Biosciences will incorporate a new subsidiary, Gufic Philippines Inc., to expand pharmaceutical distribution. The company approved a cash investment of approximately ₹2.4 Crore.
Gufic Biosciences will incorporate a subsidiary, 'Gufic Philippines Inc.', investing up to USD 250,000 (~₹2.38 Crore) to expand pharmaceutical operations in the Philippines.
Gufic BioSciences Ltd reported revenue from operations of ₹260.8 Cr (+16.6% YoY) and net profit of ₹22.3 Cr (+70.2% YoY) for Q1 FY27.
Gufic Biosciences Ltd has released its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. The report details the company's commitment to ESG standards.
Gufic Biosciences Limited has filed its Annual Report for FY 2025-26, along with the notice for its 42nd Annual General Meeting scheduled for September 4, 2026.
Gufic Biosciences will hold its 42nd AGM on September 4, 2026, via video conferencing. The register of members will be closed from August 29, 2026.
Gufic Biosciences Limited has scheduled a board meeting for August 14, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.